Teva Pharm - TEVA STOCK NEWS

Teva Pharmaceuticals announced 11 presentations on AJOVY^® (fremanezumab-vfrm) at the 2021 American Headache Society Annual Meeting from June 3-6. The research highlights AJOVY's effectiveness in migraine treatment, showcasing clinical data spanning 15 months. Key findings include the drug's significant impact on patients with comorbid conditions like depression and anxiety. AJOVY is available in single-dose injections and is indicated for preventive migraine treatment in adults. For further information, details can be found on Teva's website.

Teva Pharmaceuticals has launched the first generic version of THIOLA® (tiopronin) tablets in the U.S., aimed at preventing cystine kidney stone formation in adults and children aged 9 and above. The medication is intended for patients unresponsive to standard treatments such as increased fluid intake and dietary changes. Teva, known for its extensive portfolio of over 550 generic medicines, holds a leading market position in generics with around 1 in 11 prescriptions in the U.S. filled with its products. The company continues to focus on expanding its generic offerings, with about 100 additional products pending approval.

Teva Pharmaceuticals launched the "It’s Not OK – It’s TD" campaign to raise awareness about tardive dyskinesia (TD) and promote AUSTEDO® (deutetrabenazine) as a treatment option. The campaign encourages patients to discuss their symptoms with healthcare providers instead of coping silently. TD can affect 1 in 4 individuals on certain mental health medications, leading to significant physical and emotional impacts. Clinical studies show AUSTEDO significantly reduces TD symptoms, with sustained improvement over 145 weeks. Teva also offers resources and financial assistance to support patients during treatment.

Teva Pharmaceuticals has announced the presentation of two e-posters at the ATS International Conference from May 14-19, 2021. One poster focuses on the increased use of short-acting beta-agonist (SABA) in patients with poorly controlled asthma using the ProAir^® Digihaler^®. The second addresses real-world uncontrolled COPD therapy. These findings underscore Teva's commitment to improving respiratory disease treatments, utilizing data from their digital inhaler to inform patient management.

Teva Pharmaceuticals has launched its generic Erythromycin tablets in 250 mg and 500 mg strengths, a therapeutic equivalent to Arbor Pharmaceuticals' reference drug. These tablets are used to treat several bacterial infections and prevent rheumatic fever in penicillin-allergic patients. Teva, with a robust portfolio of nearly 550 generic medicines, leads in FDA-approved generics and holds approximately 100 first-to-file opportunities. Annual sales for Erythromycin in the U.S. exceed $49 million, indicating significant market potential for Teva's new offering.

Teva Pharmaceuticals announced new data from a 3-year study of AUSTEDO^® (deutetrabenazine) for tardive dyskinesia (TD), to be presented at the 2021 APA Virtual Annual Meeting (May 1-3). This study investigates long-term safety, quality of life (QoL), and patient outcomes in 337 patients. Results show that 79.8% reported at least one adverse event, with low incidence rates. QoL improvements were noted with significant scores change over 145 weeks. AUSTEDO is indicated for both TD and chorea associated with Huntington’s disease.

Teva Pharmaceuticals has launched the first generic isotretinoin capsules (10 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg) in the U.S. for treating severe nodular acne in non-pregnant patients aged 12 and older. This introduction adds to Teva's robust portfolio, which includes over 550 generic medicines. Isotretinoin capsules, with annual sales exceeding $158 million, offer an essential option for patients unresponsive to conventional therapies. Teva's generics division continues to lead in first-to-file opportunities, further solidifying its market presence.

Teva Pharmaceutical Industries Ltd. (TEVA) reported Q1 2021 revenues of $3,982 million, a 9% decline from Q1 2020. Profitability improved, with net debt reduced to $23.2 billion. Key products like Truxima® and AUSTEDO® showed growth, while COPAXONE revenues fell significantly in both North America and Europe. GAAP net income increased to $77 million, with EPS at $0.07. However, non-GAAP net income dropped to $699 million and diluted EPS to $0.63, reflecting a 12% decrease in adjusted EBITDA. Teva maintains a financial leverage of 69%.